
Endocrinologist

No OPD information available
Type 1 Diabetes (T1D)
Diabetic Retinopathy
Diabetic Nephropathy
Vitamin D Deficiency
Wilson Disease
Autonomic Neuropathy
Celiac Disease
Congenital Hyperinsulinism
Cystic Fibrosis
Diabetic Ketoacidosis
Diabetic Neuropathy
Familial Dysautonomia
Hypertension
Islet Cell Transplantation
Malabsorption
Malnutrition
Obesity
Type 2 Diabetes (T2D)
Kim C. Donaghue helps people with different health problems like Type 1 Diabetes, Diabetic Retinopathy, and more. She is skilled in treating conditions like Celiac Disease, Obesity, and Hypertension. Kim C. Donaghue also works with patients who have Type 2 Diabetes, Vitamin D Deficiency, and other health issues.
She uses special skills and treatments to care for her patients. Kim C. Donaghue talks with patients in a way that makes them feel comfortable and safe. Patients trust her because she listens to them and explains things clearly.
Kim C. Donaghue stays updated on the latest medical information and research. She learns about new treatments and technologies to give the best care to her patients. Kim C. Donaghue works well with other medical professionals. She shares knowledge and collaborates with colleagues to help patients.
Kim C. Donaghue's work has made a positive impact on many people's lives. She has helped patients manage their conditions and improve their health. Kim C. Donaghue's research on travel health and Type 1 Diabetes has been published in a medical journal. She is also involved in a clinical trial to study the effects of a medicine on Diabetic Retinopathy.
In summary, Kim C. Donaghue is a caring and knowledgeable healthcare provider who uses her skills to help people with various health issues. She communicates well with patients, stays updated on medical advances, and works closely with other medical professionals. Her work has had a positive impact on patients' lives, and she continues to contribute to medical research and care.
Enrollment Status: Recruiting
Published: April 04, 2025
Intervention Type: Drug
Study Drug: Fenofibrate
Study Phase: Phase 3
